Aubrak Therapeutics Overview
- Year Founded
-
2021
- Status
-
Private
- Latest Deal Type
-
Early Stage VC
- Latest Deal Amount
-
$15.8M
- Investors
-
5
Aubrak Therapeutics General Information
Description
Researcher and developer of new drugs using innovation biotechnology. The company focuses on the development of new anti-cancer drugs such as small molecule targeted protein degraders (PROTAC and molecular glue), enabling patients with drugs designed for unmet clinical need.
Contact Information
Corporate Office
- Room 393, Block A, Phase I, Zhongdan Ecological Life Science Industrial Park
- No. 3-1, Xinjinhu Road, Jiangbei New District
- Nanjing, Jiangsu
- China
Corporate Office
- Room 393, Block A, Phase I, Zhongdan Ecological Life Science Industrial Park
- No. 3-1, Xinjinhu Road, Jiangbei New District
- Nanjing, Jiangsu
- China
Aubrak Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 1. Early Stage VC | 25-Mar-2022 | $15.8M | Completed | Clinical Trials - General |
Aubrak Therapeutics Patents
Aubrak Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2024165050-A1 | Proteolysis-targeting chimera (protac) compounds and uses thereof field | Inactive | 10-Feb-2023 | ||
| WO-2022048605-A1 | Heterocyclic compound, preparation method therefor, intermediate, composition, and applications | Inactive | 04-Sep-2020 | ||
| WO-2022048605-A8 | Heterocyclic compound, preparation method therefor, intermediate, composition, and applications | Inactive | 04-Sep-2020 | C07D401/14 |
Aubrak Therapeutics Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Eastern Biopharmaceuticals | Corporation | Minority | ||
| Ennovation Ventures | Venture Capital | Minority | ||
| Hermed Capital | Venture Capital | Minority | ||
| Nanjing Jiangbei New Area Innovation Investment Fund Management | PE/Buyout | Minority | ||
| Realharmony Capital | Venture Capital | Minority |
Aubrak Therapeutics FAQs
-
When was Aubrak Therapeutics founded?
Aubrak Therapeutics was founded in 2021.
-
Where is Aubrak Therapeutics headquartered?
Aubrak Therapeutics is headquartered in Nanjing, China.
-
What industry is Aubrak Therapeutics in?
Aubrak Therapeutics’s primary industry is Drug Discovery.
-
Is Aubrak Therapeutics a private or public company?
Aubrak Therapeutics is a Private company.
-
What is Aubrak Therapeutics’s current revenue?
The current revenue for Aubrak Therapeutics is .
-
How much funding has Aubrak Therapeutics raised over time?
Aubrak Therapeutics has raised $15.8M.
-
Who are Aubrak Therapeutics’s investors?
Eastern Biopharmaceuticals, Ennovation Ventures, Hermed Capital, Nanjing Jiangbei New Area Innovation Investment Fund Management, and Realharmony Capital have invested in Aubrak Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process